1GLOBE CAPITAL LLC
recently revealed that they own 16.4% of Sinovac Biotech Ltd. (NASDAQ:SVA) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, March 26th. The investor owns 9,353,092 shares of the stock valued at $80,623,653. The filing is available through EDGAR at <a href='http://www.sec.gov/
Other hedge funds and other institutional investors have also made changes to their positions in the company. Neumann Advisory Hong Kong Ltd purchased a new position in shares of Sinovac Biotech during the 4th quarter valued at approximately $3,174,000. Spark Investment Management LLC increased its holdings in shares of Sinovac Biotech by 271.3% during the 4th quarter. Spark Investment Management LLC now owns 66,100 shares of the biopharmaceutical company’s stock valued at $520,000 after purchasing an additional 48,300 shares in the last quarter. Eqis Capital Management Inc. increased its holdings in shares of Sinovac Biotech by 4.6% during the 4th quarter. Eqis Capital Management Inc. now owns 156,492 shares of the biopharmaceutical company’s stock valued at $1,233,000 after purchasing an additional 6,953 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Sinovac Biotech during the 3rd quarter valued at approximately $163,000. Finally, Citadel Advisors LLC increased its holdings in shares of Sinovac Biotech by 189.8% during the 3rd quarter. Citadel Advisors LLC now owns 34,193 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 22,393 shares in the last quarter. Institutional investors and hedge funds own 12.62% of the company’s stock.
Shares of Sinovac Biotech Ltd. (NASDAQ:SVA) traded up $0.06 during midday trading on Monday, reaching $8.62. 1,123 shares of the company traded hands, compared to its average volume of 68,997. Sinovac Biotech Ltd. has a 12 month low of $4.60 and a 12 month high of $8.75.
Separately, BidaskClub lowered shares of Sinovac Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th.
COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3302448/1globe-capital-llctotal-shares9353092-has-stake-in-sinovac-biotech-ltd-sva.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.